Duopharma’s 1Q earnings at RM15mil


Duopharma group managing director Leonard Ariff Abdul Shatar.

PETALING JAYA: Duopharma Biotech Bhd foresees challenges from a strong US dollar, high electricity tariffs and interest rates impacting manufacturing margins and overall profitability, says group managing director Leonard Ariff Abdul Shatar.

“However, the group remains focused on enhancing operational efficiencies internally to cushion the surge in operational and finance costs caused by these challenges,” Leonard said in a statement.

Duopharma’s net profit fell 32.5% to RM15.3mil, or an earnings per share of 1.59 sen in the first quarter ended March 31 compared with RM22.6mil, or 2.38 sen posted in the same quarter last year.

Revenue dipped to RM192.9mil versus RM200.5mil.

“The marginally lower year-on-year revenue and pre-tax profit were attributed to lower demand in the prescription pharmaceutical markets, both in the private ethical and public health segments,” Duopharma said.

Follow us on our official WhatsApp channel for breaking news alerts and key updates!
   

Next In Business News

Oil eases on strong dollar, global economic news
GIP SUPPORTS MALAYSIA AIRPORTS’ JOURNEY TO GLOBAL EXCELLENCE
Asia ESG Positive Impact Consortium pledges sustainability
UMW realigns strategies to promote growth
Nvidia’s gains leave investors wondering – to cash in or buy more?
Malaysia’s competitiveness set to improve further
Genting’s plans for diversification continue to gather momentum
Winning the digital game
IJM Corp secures two construction contracts worth RM962.3mil
KAB rides data centre wave

Others Also Read